The use of circulating biomarkers for heart failure (HF) is engrained in contemporary
cardiovascular practice and provides objective information about various pathophysiological …

Important differences in comorbidities and clinical characteristics exist between women and
men with heart failure (HF). In particular, differences in the kinetics of biological circulating …

Heart failure (HF) is a major health care issue, given its high prevalence and incidence, the
rate of comorbidities, the related high health care costs, and its poor outcomes. In the last …

In the latter half of the 20th century, among participants of the Framingham Heart Study,
incidence of heart failure (HF) has declined by about a third in women but not in men and …

Heart failure (HF) affects 1–2% of the population in developed countries and~ 50% of
patients living with it are women. Compared to men, women are more likely to be older and …

Heart failure (HF) represents a global pandemic health problem with a high impact on health-
care costs, affecting about 26 million adults worldwide. The overall HF prevalence and …

Aims Despite disparities in pathophysiology and disease manifestation between male and
female patients with heart failure, studies focusing on sex differences in biomarkers are …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

Cardiovascular diseases show many sex-related differences in prevalence, etiology,
phenotype expression, and outcomes. Complex molecular mechanisms underlie this …

Since 1984, each year, more women than men die of ischemic heart disease (IHD) and
heart failure (HF), yet more men are diagnosed. Because biomarker assessment is often the …